CD44 and Familial prostate cancer: The apoptotic effect of TRAIL in combination with taxanes have been tested in the whole population of PC3 and DU145 prostate cancer cells, but also in CD44+/CD24− prostate cancer stem cells subpopulation within both cell lines to examine if this compounds can augment the anti-cancer effect of TRAIL.